Due to the dual, but opposing, effects of TNFR1 and TNFR2 that have been reported, it has been suggested that the simultaneous inhibition of TNFR1 whilst promoting TNFR2 signalling might be potentially beneficial in the treatment of MS [4]. This evidence concerns the gene TNFRSF1B and myeloid sarcoma.